ClinicalTrials.gg
CompletedNCT01333592Updated Dec 15, 2014Results posted

Long-term Study of KAD-1229 in Type 2 Diabetes Patients

A Phase 3 interventional study of KAD-1229 in Type 2 Diabetes, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-12-15.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
136
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 394 studies in Diabetes Mellitus, Type 2 with a site in Japan — 23 open to participants now, 31 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Japan.

Enrollment
243rd of 334
136 · median 284
Phase 3
188 of 394
18 open now
Registered
131st of 394
by date

Among the 394 studies in Diabetes Mellitus, Type 2 with a site in Japan, this one is the 243rd largest by enrollment of the 334 interventional ones that give a count, is one of 188 in phase 3, and was the 131st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

23 of the 394 studies in Diabetes Mellitus, Type 2 with a site in Japan are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 394 studies in Diabetes Mellitus, Type 2 with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and efficacy of KAD-1229 as combination therapy with biguanide or DPP-4 inhibitor in type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Type 2 diabetes
  • HbA1c
  • Long-term study
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy
  • Age in the 20 years or over inclusive
  • in the range of ≥ 6.5 to \< 9%

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Patients with serious diabetic complications and other serious complications
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    KAD-1229

    Drug: KAD-1229

Interventions

06

What researchers measure

Primary outcomes

  1. Incidences of Adverse Events

    Time frame: 52 weeks

Secondary outcomes

  1. Change From Baseline in HbA1c at 52 Weeks

    Time frame: at week 0 and week 52

07

Results

Posted Nov 24, 2014

Participant flow

Participant flow — Overall Study
MilestoneKAD-1229 / DPP-4 InhibitorsKAD-1229 / Biguanides
Started6769
Completed5852
Not completed917

Outcome measures

SecondaryChange From Baseline in HbA1c at 52 Weeks
Time frame:
at week 0 and week 52
Reported as:
Mean · percentage of HbA1c
Change From Baseline in HbA1c at 52 Weeks
percentage of HbA1cKAD-1229 / DPP-4 InhibitorsKAD-1229 / Biguanides
Change From Baseline in HbA1c at 52 Weeks-0.45 ± 0.69-0.28 ± 0.63
PrimaryIncidences of Adverse Events
Time frame:
52 weeks
Reported as:
Number · Participants
Incidences of Adverse Events
ParticipantsKAD-1229 / DPP-4 InhibitorsKAD-1229 / Biguanides
Incidences of Adverse Events4857

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
KAD-1229 / DPP-4 Inhibitors—1/67 (1.5%)34/67 (50.7%)
KAD-1229 / Biguanides—5/69 (7.2%)47/69 (68.1%)
Most frequent serious events
Most frequent serious events
EventKAD-1229 / DPP-4 InhibitorsKAD-1229 / Biguanides
large intestine carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/671/69
prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/671/69
acute myocardial infarctionCardiac disorders0/671/69
traumatic lung injuryRespiratory, thoracic and mediastinal disorders0/671/69
colonic polypGastrointestinal disorders0/671/69
brain contusionInjury, poisoning and procedural complications0/671/69
lumbar vertebral fractureInjury, poisoning and procedural complications0/671/69
rib fractureInjury, poisoning and procedural complications0/671/69
skull fractureInjury, poisoning and procedural complications0/671/69
Most frequent other events
Showing 10 of 11
Most frequent other events
EventKAD-1229 / DPP-4 InhibitorsKAD-1229 / Biguanides
NasopharyngitisInfections and infestations17/6730/69
BronchitisInfections and infestations2/678/69
γ-glutamyltransferase increaseInvestigations4/677/69
PharyngitisInfections and infestations6/672/69
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders5/675/69
Alanine aminotransferase increaseInvestigations0/675/69
White blood cell count increaseInvestigations3/675/69
ArthralgiaMusculoskeletal and connective tissue disorders4/671/69
Back painMusculoskeletal and connective tissue disorders4/671/69
Dental cariesGastrointestinal disorders0/674/69

Baseline characteristics

One patient in the KAD-1229 / biguanides group was excluded because of early discontinuation and no evaluable HbA1c.

Age, Continuous
Age, Continuous(years)KAD-1229 / DPP-4 InhibitorsKAD-1229 / BiguanidesTotal
Mean60.3 ± 10.656.9 ± 11.558.6 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)KAD-1229 / DPP-4 InhibitorsKAD-1229 / BiguanidesTotal
Female211839
Male465096
HbA1c
HbA1c(%)KAD-1229 / DPP-4 InhibitorsKAD-1229 / BiguanidesTotal
Mean7.47 ± 0.547.50 ± 0.667.49 ± 0.60
08

Study locations

1 site
  • Japan
    Kanto region, Chugoku region, Kyushu region, Japan
09

Timeline

Tracking since Sep 25, 2026

Results were first posted in Nov 2014, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2011
First posted
Apr 12, 2011
Primary completionActual
Aug 2012
CompletionActual
Nov 2012
Results first posted
Nov 24, 2014
Last update
Dec 15, 2014
What these dates mean
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01333592
First posted
Apr 12, 2011
Primary completion
Aug 2012
Completion
Nov 2012
Results posted
Nov 24, 2014
Last update
Dec 15, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitiglinide

Start the discussion